Between April 4, 2023, and December 26, 2024, 43 patients were screened, 40 were enrolled, and 36 received infusion (median age, 68 years [46-75]). In the infused cohort, the MRD negativity rate at ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion YK-hBCMA BB-002, despite high-risk biology and frailty representation. Depth of ...
Creative Biolabs today announced the upgrade of its next-generation drug discovery pipeline with integrated AI-driven ...
LOS ANGELES--(BUSINESS WIRE)--Physician-researchers with City of Hope ®, one of the largest cancer research and treatment organizations in the United States with its National Medical Center named Top ...
Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results